For decades, HIV vaccine scientists have struggled with the complexity of inducing neutralizing antibodies, which are crucial for preventing HIV infection. Traditional vaccine approaches targeting the envelope glycoprotein of HIV—the virus’s outermost and most variable structure—have required extensive immunization schedules involving numerous booster shots to achieve any measurable neutralizing response. This has hindered widespread vaccine deployment, especially in regions most affected by HIV.

Led by Dr. Amelia Escolano at The Wistar Institute’s Vaccine and Immunotherapy Center, the team engineered a novel HIV envelope protein immunogen, designated WIN332. Contrary to established scientific doctrine, which emphasized the necessity of maintaining a specific sugar molecule called the N332-glycan for antibody binding, the researchers purposefully removed this glycan from the V3-glycan epitope. This unconventional strategy not only defied conventional wisdom but also facilitated rapid induction of neutralizing antibodies with remarkable efficacy.

Following a single injection of WIN332, nonhuman primates developed low but detectable levels of neutralizing antibodies targeting HIV within just three weeks—an unprecedented response rate compared to previous vaccine candidates. The significance of this is profound: reducing the immunization timeline to a single dose while achieving early neutralization represents a major leap in HIV vaccine technology. A subsequent booster shot with a related immunogen further amplified this immune response, indicating the potential for an abbreviated yet potent vaccination regimen.

The V3-glycan region of the HIV envelope has long been a focal point in vaccine design due to its conserved epitopic nature across diverse HIV strains. However, its intricate glycosylation patterns have presented challenges for antibody accessibility and efficacy. By engineering WIN332 to lack the previously indispensable N332-glycan, the Wistar team identified and characterized two distinct classes of neutralizing antibodies. The first, Type I antibodies, conform to classical understanding and require the N332 glycan for effective binding. The second, newly discovered Type II antibodies, do not depend on this sugar, expanding the scope of neutralization mechanisms available for vaccine design.

This dichotomy in antibody types opens new avenues for creating vaccines that are effective against the wide variability of circulating HIV strains worldwide. It suggests that antibodies can target the virus through multiple molecular pathways, circumventing viral evasion strategies that hail from glycosylation heterogeneity. The practical upshot is the potential development of broadly neutralizing vaccines with improved cross-strain protection and scalability.

Beyond the molecular innovation, this vaccine candidate holds immense promise for global public health. HIV remains a profound challenge, with millions suffering from the virus globally, particularly in low-resource settings. Current vaccine candidates’ requirement for numerous injections over protracted periods has been a major barrier to effective immunization programs. A vaccine platform like WIN332, capable of generating neutralization with as few as three administrations, offers a transformative prospect for accessibility, compliance, and cost reduction.

The research drew intense interest from leading global health organizations eager to fast-track WIN332 into human clinical trials. Such trials will determine the vaccine’s safety and efficacy in diverse human populations and potentially pave the way to mass immunization campaigns. Meanwhile, the team continues to refine the vaccine candidate, optimizing subsequent immunogens to maximize neutralization potency and durability following abbreviated immunization schedules.

The study’s success is underpinned by the collaborative efforts of multidisciplinary experts from The Wistar Institute and partner institutions, including Tulane National Primate Research Center, University of Georgia, Beth Israel Deaconess Medical Center, Scripps Research Institute, and University of Pennsylvania. Their combined expertise extends across virology, immunology, biochemistry, and translational medicine, reinforcing the study’s robustness and advancing HIV vaccine science.

Funding from prestigious bodies such as the National Institute of Allergy and Infectious Diseases and the Bill and Melinda Gates Foundation has been instrumental in supporting this innovative research. Furthermore, the study was strengthened by advanced glycoscience resources and postdoctoral fellowships enabling focused experimental design and execution.

Dr. Escolano and her team’s breakthrough demonstrates that challenging prevailing dogma in biomedical research can yield unexpected and highly impactful findings. By eschewing the conventional mandate to preserve the N332 glycan, they have effectively expanded the immunological toolkit against HIV, rekindling hope for a safe, effective, and widely deployable vaccine against one of the world’s most persistent pathogens.

As this vaccine candidate enters the next phase of development, its trajectory embodies the broader imperative in vaccine research: harnessing molecular insights to create simpler, faster, and more potent immunization strategies that serve global health equitably. Should WIN332’s promise hold true in human trials, it will represent a historic stride towards ending the HIV/AIDS epidemic.

Subject of Research: Animals (Nonhuman Primates)

Article Title: Rapid elicitation of neutralizing Asn332-glycan-independent antibodies to the V3-glycan epitope of HIV-1 Env in nonhuman primates

News Publication Date: 3-Feb-2026

Web References:
https://www.nature.com/articles/s41590-025-02408-z

References:
Escolano, A., Relano-Rodriguez, I., Du, J., Lin, Z.J., Kerwin, M., Tarquis-Medina, M., Urbano, E., Cui, J., Habib, R., Agostino, C., Ghosh, S., Park, J., Boroughs, C., Shukla, N., Weiner, D.B., Kulp, D.W., Pallesen, J., Watkins, M., Veazey, R.S., Zhao, P., Wells, L., Seaman, M.S., Walsh, A.A., Melo, M.B., Irvine, D.J., Shaw, G.M., Hahn, B.H. Rapid elicitation of neutralizing Asn332-glycan-independent antibodies to the V3-glycan epitope of HIV-1 Env in nonhuman primates. Nature Immunology, 2026.

Image Credits: The Wistar Institute

Keywords: Vaccination, HIV vaccine, neutralizing antibodies, HIV-1 Envelope protein, V3-glycan epitope, WIN332 immunogen, N332-glycan, nonhuman primates, immunotherapy, infectious diseases

Hemagglutinin (HA), the spike protein that protrudes from the influenza virus surface, plays a pivotal role in enabling viral entry into host cells by binding to sialic acid receptors. This makes HA the prime target for immune responses and antiviral strategies. However, the constant evolution of HA, especially in highly pathogenic avian influenza strains like clade 2.3.4.4b H5N1, has complicated vaccine development and therapeutic design. The research team addresses this challenge by isolating and characterizing potent human monoclonal antibodies that bind with exceptional specificity to this clade’s HA, neutralizing the virus before it can initiate infection.

To achieve this, the researchers employed an array of sophisticated techniques ranging from single B cell sorting from convalescent individuals who recovered from H5N1 infection, to next-generation sequencing for antibody gene retrieval. Structural biology methods such as cryo-electron microscopy and X-ray crystallography were instrumental in revealing the precise binding epitopes on the HA molecule. The team determined that these antibodies primarily target conserved regions of the HA head domain, which are critical for receptor binding, thereby blocking the virus’s ability to attach and fuse with host cells.

Of special note is the high degree of somatic hypermutation observed in these monoclonal antibodies, reflective of an intense affinity maturation process during the immune response. This molecular fine-tuning suggests that human immune systems, under certain conditions, can generate antibodies of remarkable potency and breadth against otherwise evasive viral antigens. The study’s findings challenge prior assumptions that highly mutable H5N1 viruses invariably escape neutralization by adaptive immunity.

Functionally, the monoclonal antibodies demonstrated broad neutralizing activity across multiple viral isolates within clade 2.3.4.4b, including those bearing mutations previously associated with immune escape. In vitro assays showed these antibodies could inhibit viral entry at picomolar concentrations, highlighting their therapeutic promise. When tested in relevant animal models, passive transfer of the antibodies conferred significant protection, reducing viral load, morbidity, and mortality.

The detailed structural characterization provided insights into the mechanisms governing antibody efficacy. The majority of antibodies examined made extensive contacts with the receptor-binding site and adjacent antigenic loops on HA, effectively locking the protein in a conformation that precludes receptor engagement. This mode of neutralization is akin to corralled gatekeeping, where the virus’s key to entry is blocked with molecular precision.

Importantly, this research underscores the feasibility of leveraging the human antibody repertoire for rapid therapeutic development against emerging influenza strains. Current antiviral drugs face the dual challenge of drug resistance and limited spectrum, while vaccine updates lag behind viral evolution. Monoclonal antibodies serve as a complementary line of defense, applicable both for treatment and as prophylaxis during outbreaks.

Furthermore, the study highlights the value of integrating structural virology with immunology and genomics to accelerate antibody discovery. By precisely decoding the interactions between antibodies and HA at atomic resolution, scientists can rationally design improved monoclonals or guide vaccine antigen selection to elicit similar protective responses.

The implications of these findings extend beyond H5N1, as many zoonotic influenza strains share structural motifs in their HA proteins. Thus, the principles and methodologies elucidated here might serve as templates for combating other high-threat viruses poised for human transmission. The emergence of clade 2.3.4.4b H5N1 in recent years underlines the urgent need for such versatile medical countermeasures.

In a broader context, the study also sheds light on the evolutionary pressures shaping viral antigenicity and immune escape. The conserved epitopes targeted by these monoclonals appear under functional constraints, limiting the virus’s capacity to mutate without compromising infectivity. This constriction is a critical aspect exploited by the immune system to achieve durable protection.

Looking ahead, translation of these monoclonal antibodies into clinical applications will require scalable production, optimization for extended half-life, and rigorous safety evaluation. Nonetheless, their documented potency and breadth position them as frontrunners in the growing arsenal against influenza pandemics.

Moreover, the insights gathered about clade 2.3.4.4b H5N1’s hemagglutinin structure and immune vulnerabilities provide a foundational blueprint for next-generation vaccine design. By focusing on conserved receptor-binding sites, novel immunogens could provoke broadly neutralizing antibody responses in diverse populations, potentially surpassing the protective efficacy of seasonal flu vaccines.

This research represents a confluence of multidisciplinary efforts, spanning immunology, structural biology, virology, and therapeutic antibody engineering. The collaborative approach exemplifies how modern science can rapidly pivot to address emergent global health threats, transforming detailed molecular knowledge into actionable medical interventions.

In sum, Alzua and colleagues’ work heralds a new frontier in influenza immunotherapy, demonstrating that human monoclonal antibodies can effectively disarm one of nature’s most fearsome viral foes. Their elegant dissection of antibody-HA interactions not only deepens our understanding of viral pathogenesis but also lights the path toward innovative countermeasures capable of saving countless lives.

As the scientific community continues to grapple with the evolving influenza landscape, these findings may well catalyze a paradigm shift, ushering in an era where antibody-based therapeutics routinely complement vaccines, antiviral agents, and public health measures to thwart future influenza pandemics before they take hold.

This landmark study underscores the power of harnessing human immunity’s precision tools, reminding us that despite viral mutability and adaptability, vulnerabilities remain—vulnerabilities that science can exploit to safeguard humanity.

Subject of Research: Human monoclonal antibodies targeting clade 2.3.4.4b H5N1 hemagglutinin

Article Title: Human monoclonal antibodies that target clade 2.3.4.4b H5N1 hemagglutinin

Article References:

Alzua, G.P., León, A.N., Yellin, T. et al. Human monoclonal antibodies that target clade 2.3.4.4b H5N1 hemagglutinin.
Nat Commun (2025). https://doi.org/10.1038/s41467-025-66829-y

Image Credits: AI Generated

Amid this pressing demand, scientific attention has pivoted towards LC16m8, a live-attenuated vaccinia virus vaccine originally engineered in Japan for smallpox prevention. Due to its established safety profile and immunogenic potential, LC16m8 was granted approval for mpox immunization in 2022. Despite encouraging results in preliminary animal and human studies, a comprehensive immunological characterization of the vaccine remained elusive. Addressing this gap, researchers at The University of Tokyo embarked on an intensive multi-species investigation, combining mouse models, non-human primates, and human clinical samples to dissect the immune mechanisms elicited by LC16m8.

Under the leadership of Associate Professor Kouji Kobiyama and Professor Ken J. Ishii, the research team undertook an expansive experimental approach, integrating immunological assays with pathological evaluations. Three distinct genetically diverse mouse strains—BALB/c, C57BL/6J, and CAST/EiJ—were immunized with LC16m8 to parse strain-specific immune signatures and protection dynamics. These murine models were essential to deciphering both cellular and humoral immune responses triggered by the vaccine and to evaluating its efficacy in reducing viral replication within target organs, specifically lung tissues.

Complementing the murine studies, cynomolgus monkeys received high doses of LC16m8 to monitor safety parameters rigorously. The primate model allowed detailed observation of physiological indicators such as body weight, temperature regulation, and hematological markers, alongside the onset of any localized or systemic side effects. Notably, the vaccine induced mild skin lesions characteristic of poxvirus vaccination without compromising the overall health status of the subjects, reinforcing its safety profile in a model closer to humans.

To translate these findings into human relevance, the team analyzed blood specimens from healthy adult volunteers vaccinated with LC16m8. Serological assessments focused on quantifying neutralizing antibody titers against a spectrum of MPXV variants, delivering insight into the vaccine’s breadth of immune coverage. Importantly, the absence of serious adverse events during the follow-up period affirms the vaccine’s tolerability and potential for broad clinical application.

The murine studies revealed that LC16m8 invokes robust humoral immunity across all tested strains, with marked activation of germinal center B cells and follicular helper T cells—key players in facilitating strong, durable antibody responses. CAST/EiJ mice, in particular, exhibited pronounced viral clearance in lung tissue, illustrating that immune efficacy extends beyond antibody induction to conferred protection against viral replication in critical organs.

Data from cynomolgus monkeys further corroborated these results by demonstrating localized reactogenicity typical of vaccinia virus vaccines without adverse systemic effects. This nuanced safety profile is vital for public health considerations, ensuring minimal risk as the vaccine scales toward human usage.

In human recipients, LC16m8 elicited widespread neutralizing antibodies capable of cross-reactivity against multiple contemporary MPXV lineages. Such immune cross-protection is crucial given the rapid mutation and evolution of poxviruses, which often undermine vaccine efficacy through antigenic drift. These findings position LC16m8 as a promising candidate for adeptly handling the antigenic diversity characteristic of current mpox outbreaks.

Beyond reaffirming LC16m8’s immediate utility, this study’s integrative, cross-species methodology sets a new standard for vaccine evaluation against emerging infectious diseases. By thoroughly dissecting immune correlates of protection and safety, such research expedites the trajectory from laboratory bench to clinical application—a critical advantage in outbreak scenarios demanding swift immunization responses.

Associate Professor Kobiyama emphasizes that with validated efficacy and safety credentials, LC16m8 could rapidly gain regulatory approvals and be deployed particularly in regions disproportionately affected by mpox, notably African nations where mpox remains endemic. Wide-scale vaccination campaigns could markedly reduce transmission rates, alleviate the strain on healthcare infrastructure, and ultimately inch closer to possible eradication.

Nonetheless, the research team acknowledges the necessity of further investigations to refine dosing regimens, evaluate vaccine performance in immunocompromised and naive populations, and explore innovative vaccine platforms that may complement or supersede current modalities. Such extended studies are imperative to maximize long-term vaccine impact and adapt to evolving viral landscapes.

The implications of this research transcend mpox, offering a conceptual and practical framework to devise global surveillance and response infrastructures tailored to myriad infectious threats. Building resilience in medical preparedness hinges on generating adaptable vaccines coupled with robust immunological understanding—goals that LC16m8 research significantly advances.

In aligning with technological advancements and interdisciplinary collaboration, The Institute of Medical Science at The University of Tokyo continues to spearhead transformative biomedical investigations. Their commitment to pioneering vaccine science stands to revitalize public health paradigms, not only confronting mpox challenges but also preempting future pandemic episodes.

Subject of Research: Animals
Article Title: Immunological analysis of LC16m8 vaccine: preclinical and early clinical insights into mpox
News Publication Date: 1-May-2025
Web References: https://doi.org/10.1016/j.ebiom.2025.105703
References: Authors: Kouji Kobiyama, Daichi Utsumi, Yu Kaku, et al. "Immunological analysis of LC16m8 vaccine: preclinical and early clinical insights into mpox," eBioMedicine, Volume 115, May 2025. DOI: 10.1016/j.ebiom.2025.105703
Image Credits: World Bank Photo Collection from Openverse

Keywords: Vaccine research, Vaccine development, Monkeypox, Infectious diseases, Viral infections, Preventive medicine, Clinical medicine, Human health, Pharmaceuticals, Microbial infections

Zika virus is notorious for its stealthy approach. Upon entering the host’s system, it seeks out dendritic cells, a vital component of the immune system responsible for alerting T cells. This interaction is akin to a horror movie where the unsuspecting victims remain unaware of the lurking danger. The virus cunningly suppresses the alert signals produced by dendritic cells, preventing them from calling for help from other immune components. This subversion effectively allows the virus to thrive unnoticed, evading the host’s immune detection while incapacitating its primary defenders.

In sharp contrast, dengue virus opts for a more aggressive maneuver. Upon invading dendritic cells, it incites a dramatic immune response, compelling these cells to release pro-inflammatory cytokines. This flurry of immune activity serves as a double-edged sword: while it attempts to mount a defense against the virus, it simultaneously provides the dengue virus with an opportunity to spread to new host cells. The body’s overzealous response can inadvertently lead to severe symptoms and complications—a prime example of how a viral strategy can turn the host’s immune defense against itself.

The study undertaken by the researchers was groundbreaking in elucidating these distinct viral tactics. By utilizing cutting-edge techniques, the team isolated dendritic cells infected specifically by either Zika or dengue virus. They scrutinized the gene expression profiles of these cells to uncover the differential immune responses elicited by each virus. This focused analysis revealed that Zika virus actively inhibits a critical molecule known as NF-κB p65 within dendritic cells. This inhibition traps the cells in an immature state, rendering them incapable of effectively activating T cells, the soldiers of the immune system.

This intricate dynamic between Zika virus and the immune system raises important questions about the reasons behind the varying immune responses observed in infected individuals. According to Ying-Ting Wang, a pivotal figure in the study, this inhibition may explain why Zika virus often elicits a milder immune response compared to dengue virus, thereby facilitating its silent spread within hosts. The implications extend beyond individual infections, as this understanding may shed light on how Zika virus breaches immune defenses in critical sites, such as the placenta, leading to fetal infections.

As the global climate continues to evolve, the risk posed by vector-borne diseases cannot be understated. Recent years have shown an alarming increase in dengue infections worldwide, with the World Health Organization noting a record-high incidence. In 2024 alone, estimates suggested that dengue virus afflicted between 100 million and 400 million individuals globally, culminating in the emergence of cases in regions previously untouched by the virus, such as San Diego County. This underscores the urgency of advancing research and development efforts aimed at combating flavivirus infections.

In response to this escalating threat, the research team, led by LJI Professor Sujan Shresta and UC San Diego Professor Aaron Carlin, is forging ahead with innovative vaccine initiatives. Their collaborative efforts are centered around harnessing T cells to effectively target and neutralize Zika virus, dengue virus, and other related pathogens. Shresta emphasizes that the ultimate aspiration is to formulate vaccines that can combat these complex viruses, utilizing the insights garnered from their research on immune manipulation.

The quest for effective vaccines against Zika and dengue is fraught with challenges, yet progress is critical. Numerous flaviviruses exhibit potential pandemic characteristics, and the WHO has highlighted these viruses—Zika and dengue included—as key areas for intensified research attention. The development of a "pan-flavivirus" vaccine could represent a transformative leap forward in public health, safeguarding populations from a spectrum of closely related pathogens.

In parallel, the research team’s efforts extend beyond vaccine development. Carlin is keen on exploring antiviral options that might disrupt Zika’s suppression of NF-κB p65, potentially opening avenues for novel therapeutic interventions. By understanding how dengue induces a hyper-stimulated immune state, researchers hope to design precision therapies that mitigate severe outcomes without compromising the immune system’s natural ability to combat viral threats.

The study ultimately serves as a clarion call to the scientific community, emphasizing the necessity of addressing flavivirus infections not only from a research perspective but also through practical public health initiatives. By fostering a comprehensive understanding of how Zika and dengue viruses operate, researchers are positioning themselves to outsmart these viral adversaries, contributing to the broader goal of safeguarding global health. With the combined might of innovative research and a unified commitment to tackling these infectious threats, there remains hope for effective strategies that will one day render both Zika and dengue harmless in human populations.

In conclusion, the divergent strategies of Zika and dengue viruses illuminate the complexity of host-pathogen interactions. As research progresses, it becomes increasingly clear that understanding these relationships is not merely an academic exercise, but a vital endeavor that holds the potential to save countless lives through the development of effective vaccines and therapies.

Subject of Research: Flavivirus infections, immune responses
Article Title: Zika but not Dengue Virus Infection Limits NF-κB Activity in Human Monocyte-Derived Dendritic Cells and Suppresses their Ability to Activate T Cells
News Publication Date: 25-Mar-2025
Web References: N/A
References: N/A
Image Credits: La Jolla Institute for Immunology

Keywords: Zika virus, Dengue virus, NF-κB, Immune response, Flavivirus, Vaccines, Viral pathogenesis, Public health, Mosquito-borne diseases, Vaccine development

The candidate vaccine being tested represents a novel approach, utilizing a platform that combines an attenuated and killed rabies virus vaccine with additional protein components derived from the Lassa virus. Rabies vaccines have a proven safety record, being administered to millions worldwide, including children and pregnant women, with minimal side effects. This background lends credibility to the new vaccine’s potential for safe human use, though its efficacy against LASV remains to be evaluated through rigorous clinical trials.

The significance of addressing the Lassa virus cannot be overstated. This virus is the causative agent of a severe viral hemorrhagic fever that inflicts a particularly high mortality rate among those who contract the illness. In fact, data suggests that around 30% of survivors experience permanent hearing loss, a morbidity that underscores the virus’s devastating effects. Endemic to West Africa, Lassa virus poses a serious public health threat, with estimates suggesting that there are between 100,000 and 300,000 infections annually, resulting in approximately 5,000 fatalities.

Notably, transmission of Lassa virus can occur not only through direct contact with infected rodents, its primary reservoir, but also through person-to-person interactions, thus complicating containment strategies. The recent case of a middle-aged resident from Iowa, who tragically succumbed to Lassa fever after returning from West Africa, illustrates the urgent need for preventive measures, including the development of effective vaccines. This incident marked the ninth recorded case of Lassa fever within the United States since 1969, raising alarms about the potential for outbreaks beyond endemic regions.

The phase 1 clinical trial currently underway is primarily focused on evaluating the safety and immunogenicity of the candidate vaccine. The study is designed to be a dose-ranging trial, meaning that it will assess various doses to identify the optimal amount that elicits a strong immune response without causing adverse effects. Enrollment is open to healthy volunteers, which is crucial as it helps to establish a foundational understanding of how human subjects might respond to the vaccine, thereby laying the groundwork for future phases of research.

The historical context of rabies vaccination enhances the foundation on which this trial is built. Rabies vaccines have been in use for decades and are well-regarded for their safety and efficacy. They have been instrumental in preventing one of the deadliest viral infections known to humanity. By employing a similar methodology in developing a LASV vaccine, researchers are drawing from a robust history of vaccine development while innovating to combat a new viral threat.

The partnership between Thomas Jefferson University and the University of Maryland represents a concerted effort to harness the collective expertise of leading institutions in the field of infectious diseases. This collaboration aims not only to develop a vaccine but also to foster a research environment in which public health can adapt to emerging viral threats. The support of funding from the National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases, is pivotal in enabling this critical research endeavor. Such financial backing underlines the importance of public investment in tackling infectious diseases that have global implications.

In a world still grappling with the aftermath of the COVID-19 pandemic, the focus on developing vaccines for emerging viruses like Lassa is more pressing than ever. The global health landscape continuously evolves, with pathogens potentially crossing geographic boundaries due to increased travel and urbanization. This trial serves as a reminder of the ongoing battle against infectious diseases and highlights the need for constant vigilance and innovative solutions in vaccine development.

The landscape of vaccine research is ever-changing, and the potential for breakthroughs like this one is a beacon of hope in public health circles. Each phase of trial not only brings new data but also inspires confidence that the scientific community is committed to understanding and combating viral pathogens. The aspirations tied to this trial extend beyond individual health; they resonate within the broader context of global health security.

As the trial progresses, anticipation will grow surrounding the insights garnered from participant responses. A successful outcome could pave the way for a licensed vaccine capable of saving lives and preventing outbreaks in endemic regions. Engaging with volunteers for such trials is essential, as their contributions can hasten the pace of medical breakthroughs while underscoring the importance of public participation in scientific research.

In conclusion, the Lassa virus vaccine trial being conducted by Thomas Jefferson University and the University of Maryland is not just another study; it is a critical step in the fight against a potentially lethal disease. The success of this endeavor could have profound implications for public health strategies worldwide and reaffirm the importance of vaccine development as a cornerstone of disease prevention. The results from this clinical trial could reshape how we approach not only Lassa fever but future viral threats as well.

Subject of Research: Vaccine development for Lassa virus
Article Title: Thomas Jefferson University Launches Phase 1 Clinical Trial for Lassa Virus Vaccine
News Publication Date: October 2023
Web References: Thomas Jefferson University
References: None available
Image Credits: None available

Keywords: Lassa virus, vaccine trial, rabies vaccine, public health, clinical research, immunogenicity, infectious diseases, protective measures, global health, NIH funding, phase 1 clinical trial, vaccine development.